CTCE-9908
CAS No. : 1030384-98-5
| Size | Price | Stock |
|---|---|---|
| 1mg | $280 | In-stock |
| 5mg | $690 | In-stock |
| 10mg | $966 | In-stock |
| 25mg | $1545 | In-stock |
| 50mg | $2000 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P1103 |
| M.Wt: | 1927.25 |
| Formula: | C86H147N27O23 |
| Purity: | >98 % |
| Solubility: | H2O : 33.33 mg/mL (ultrasonic) |
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells[1][2].
In Vitro: CTCE-9908 (0-300 μg/mL; for 10 d) inhibits migration and growth in CXCR4-expressing in ovarian cancer cell lines (IGROV, TOV21G and SKOV3). CTCE-9908 inhibits ovarian cancer cell migration to CXCL12. CTCE-9908 does not cause apoptosis or cellular senescence, but induces multinucleation, G2-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE-9908 deregulates DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G2-M phases of the cell cycle[1].
In Vivo: CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg in FVB/N TgN (MMTV-PyMT)634 male mice[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- CTCE-9908
- Cat. No.:
- HY-P1103
- Quantity:
Your information is safe with us.